1061 — Essex Bio-Technology Share News
0.000.00%
- HK$1.15bn
- HK$693.22m
- HK$1.81bn
Declares An Interim Dividend Of Hk$0.04 Per Share
Brief: Essex Bio-Technology Sees Decrease In Profit By 15% For Six Months
Brief: Essex Bio-Technology FY Profit HK$346 Mln
Brief: Essex Bio-Technology Resolved To Declare An Interim Dividend Of Hk$0.04 Per Share
Brief: Essex Bio-Technology Sees Revenue Of HK$737.4 Million For Six Months
Brief: Essex Bio-Technology Announces Product Interests Transfer Agreement With Parkson Pharmaceutical
Brief: Essex Bio-Technology Says Unaudited Revenue Of Hk$438 Mln For Four Months Ended 30 April 2021
Brief: Essex Bio-Technology Posts FY Profit Of HK$218.9 Mln
Brief: Essex Bio-Technology Received Positive Outcome Of U.S. FDA - Second Phase 3 Clinical Trial In Dry Eye Disease
Brief: Essex Bio-Technology 9-Month Unaudited Rev About HK$645 Mln
Development & Exclusive License Agreement
Development License Agreement
Development Of Biopharmaceutical Ophthalmic Product
Brief: Essex Bio-Technology Says Ngiam Hian Leng Malcom Appointed As Executive Director
Brief: Essex Bio-Technology Says Units Entered Intellectual Property License Agreement
Brief: Essex Bio-Technology & Units To Borrow US$25 Million
Brief: Essex Bio-Technology Says Zhong Sheng Resigned As Executive Director
HK-listed Essex Bio-Technology sinks to 3-week low on weak earnings outlook amid coronavirus
Brief: Essex Bio-Technology Sees Profit For Five Months Decrease By About 70%